Non-small cell lung cancer

News

Immutep investors spooked by LAG-3 failure in lung cancer

Friday the 13th has turned into a horror story for Immutep, whose share price has collapsed after it abandoned a pivotal trial of its LAG-3 drug efti.

News

Hernexeos box, two pills, and pill bottle

Boehringer gets FDA's second 'national priority' approval

Boehringer Ingelheim's lung cancer drug Hernexeos has become the second medicine approved after an FDA national priority review.

News

FDA starts review of Summit's VEGFxPD-1 bispecific

Summit moves ahead in the race to bring a VEGFxPD-(L)1 drug to market, after the FDA started a review of ivonescimab in lung cancer.

News

Genmab ends lung cancer drug development

Genmab has decided to stop development of a drug for cancer, acasunlimab for non-small cell lung cancer, following a review of its pipeline.

News

AZ's ATR inhibitor ceralasertib flunks lung cancer test

AstraZeneca has had a setback in its oncology pipeline, as AKT inhibitor ceralasertib fails to improve survival in a phase 3 lung cancer trial.

News

Two boxes and bottles of Rybrevant Faspro

J&J's subcutaneous Rybrevant cleared by FDA

J&J has claimed FDA approval for Rybrevant Faspro, a subcutaneous version of the lung cancer therapy central to its blockbuster hopes for the drug.

Immutep investors spooked by LAG-3 failure in lung cancer

Boehringer gets FDA's second 'national priority' approval

FDA starts review of Summit's VEGFxPD-1 bispecific

Genmab ends lung cancer drug development

AZ's ATR inhibitor ceralasertib flunks lung cancer test

J&J's subcutaneous Rybrevant cleared by FDA

Scribe Therapeutics joins the IPO queue

Discover a new era of healthcare panel engagement: Grounded ...

Non-small cell lung cancer

Editor's Picks